Search Results

There are 6252 results for: content related to: Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease

  1. High level of fecal calprotectin at age 2 months as a marker of intestinal inflammation predicts atopic dermatitis and asthma by age 6

    Clinical & Experimental Allergy

    Volume 45, Issue 5, May 2015, Pages: 928–939, L. Orivuori, K. Mustonen, M. C. de Goffau, S. Hakala, M. Paasela, C. Roduit, J.-C. Dalphin, J. Genuneit, R. Lauener, J. Riedler, J. Weber, E. von Mutius, J. Pekkanen, H. J. M. Harmsen, O. Vaarala and the PASTURE Study Group

    Version of Record online : 16 APR 2015, DOI: 10.1111/cea.12522

  2. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 12, Issue 6, June 2006, Pages: 524–534, Michael R. Konikoff and Lee A. Denson

    Version of Record online : 14 DEC 2006, DOI: 10.1097/00054725-200606000-00013

  3. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 18, Issue 12, December 2012, Pages: 2218–2224, Geert D'Haens, Marc Ferrante, Severine Vermeire, Filip Baert, Maja Noman, Liesbeth Moortgat, Patricia Geens, Doreen Iwens, Isolde Aerden, Gert Van Assche, Gust Van Olmen and Paul Rutgeerts

    Version of Record online : 16 FEB 2012, DOI: 10.1002/ibd.22917

  4. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings

    Inflammatory Bowel Diseases

    Volume 14, Issue 1, January 2008, Pages: 40–46, Taina Sipponen, Erkki Savilahti, Kaija-Leena Kolho, Hannu Nuutinen, Ulla Turunen and Martti Färkkilä

    Version of Record online : 16 NOV 2007, DOI: 10.1002/ibd.20312

  5. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control

    Inflammatory Bowel Diseases

    Volume 18, Issue 11, November 2012, Pages: 2018–2025, Patrick F. van Rheenen

    Version of Record online : 24 JAN 2012, DOI: 10.1002/ibd.22896

  6. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

    Inflammatory Bowel Diseases

    Volume 15, Issue 8, August 2009, Pages: 1190–1198, Javier P. Gisbert, Fernando Bermejo, Jose-Lázaro Pérez-Calle, Carlos Taxonera, Isabel Vera, Adrian G. McNicholl, Alicia Algaba, Pilar López, Natalia López-Palacios, Marta Calvo, Yago González-Lama, Jose-Antonio Carneros, Marta Velasco and José Maté

    Version of Record online : 16 MAR 2009, DOI: 10.1002/ibd.20933

  7. You have free access to this content
    Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis

    Journal of Internal Medicine

    Volume 270, Issue 1, July 2011, Pages: 50–57, K. Andréasson, A. Scheja, T. Saxne, B. Ohlsson and R. Hesselstrand

    Version of Record online : 9 JAN 2011, DOI: 10.1111/j.1365-2796.2010.02340.x

  8. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes

    Inflammatory Bowel Diseases

    Volume 15, Issue 12, December 2009, Pages: 1851–1858, Alain M. Schoepfer, Christoph Beglinger, Alex Straumann, Michael Trummler, Pietro Renzulli and Frank Seibold

    Version of Record online : 21 MAY 2009, DOI: 10.1002/ibd.20986

  9. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases

    Alimentary Pharmacology & Therapeutics

    Volume 43, Issue 10, May 2016, Pages: 1069–1079, A. Buisson, E. Vazeille, R. Minet-Quinard, M. Goutte, D. Bouvier, F. Goutorbe, B. Pereira, N. Barnich and G. Bommelaer

    Version of Record online : 8 MAR 2016, DOI: 10.1111/apt.13585

  10. You have free access to this content
    Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors

    Arthritis Care & Research

    Volume 68, Issue 7, July 2016, Pages: 899–906, José Inciarte-Mundo, Maria Victoria Hernández, Virginia Ruiz-Esquide, Sonia Raquel Cabrera-Villalba, Julio Ramirez, Andrea Cuervo, Mariona Pascal, Jordi Yagüe, Juan D. Cañete and Raimon Sanmarti

    Version of Record online : 23 JUN 2016, DOI: 10.1002/acr.22795

    Corrected by:

    Erratum: Incorrect Value in Table 2 in the Article by Inciarte-Mundo et al (Arthritis Care Res [Hoboken], July 2016)

    Vol. 69, Issue 1, 155, Version of Record online: 27 DEC 2016

  11. Induction of calprotectin release by Porphyromonasgingivalis lipopolysaccharide in human neutrophils

    Oral Microbiology and Immunology

    Volume 19, Issue 3, June 2004, Pages: 182–187, J. Kido, R. Kido, Suryono, M. Kataoka, M. K. Fagerhol and T. Nagata

    Version of Record online : 26 APR 2004, DOI: 10.1111/j.0902-0055.2004.00139.x

  12. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children

    Inflammatory Bowel Diseases

    Volume 14, Issue 3, March 2008, Pages: 359–366, Marc A. Sidler, Steven T. Leach and Andrew S. Day

    Version of Record online : 29 NOV 2007, DOI: 10.1002/ibd.20336

  13. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases

    Journal of Gastroenterology and Hepatology

    Volume 29, Issue 7, July 2014, Pages: 1406–1412, Keisuke Inoue, Tomoki Aomatsu, Atsushi Yoden, Takeru Okuhira, Emiri Kaji and Hiroshi Tamai

    Version of Record online : 15 JUL 2014, DOI: 10.1111/jgh.12578

  14. You have free access to this content
    Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease

    Methodology Review

    The Cochrane Library

    Reena Khanna, Sigrid A Nelson, Brian G Feagan, Geert D'Haens, William J Sandborn, GY Zou, John K MacDonald, Claire E Parker, Vipul Jairath and Barrett G Levesque

    Published Online : 8 AUG 2016, DOI: 10.1002/14651858.CD010642.pub2

  15. Effects of calprotectin in avridine-induced arthritis

    APMIS

    Volume 103, Issue 1-6, January 1995, Pages: 233–240, JOHAN G. Brun, GEIR HÅLand, HANS-JACOB Haga, MAGNE K. Fagerhol and ROLAND Jonsson

    Version of Record online : 15 AUG 2009, DOI: 10.1111/j.1699-0463.1995.tb01100.x

  16. Calprotectin Induces IL-6 and MCP-1 Production via Toll-Like Receptor 4 Signaling in Human Gingival Fibroblasts

    Journal of Cellular Physiology

    Volume 232, Issue 7, July 2017, Pages: 1862–1871, Yasufumi Nishikawa, Yukari Kajiura, Jung Hwan Lew, Jun-ichi Kido, Toshihiko Nagata and Koji Naruishi

    Version of Record online : 6 JAN 2017, DOI: 10.1002/jcp.25724

  17. Effects of Human Calprotectin (L1) on In Vitro Immunoglobulin Synthesis

    Scandinavian Journal of Immunology

    Volume 40, Issue 6, December 1994, Pages: 675–680, J. G. BRUN, E. ULVESTAD, M. K. FAGERHOL and R. JONSSON

    Version of Record online : 29 JUN 2006, DOI: 10.1111/j.1365-3083.1994.tb03523.x

  18. Plasma Calprotectin Predicts Mortality in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

    Journal of Interventional Cardiology

    Volume 23, Issue 2, April 2010, Pages: 123–129, LOUISE J. N. JENSEN, SUNE PEDERSEN, METTE BJERRE, RASMUS MOGELVANG, JAN SKOV JENSEN and ALLAN FLYVBJERG

    Version of Record online : 12 MAR 2010, DOI: 10.1111/j.1540-8183.2010.00532.x

  19. You have free access to this content
    Emerging role of calprotectin in gastroenterology

    Journal of Gastroenterology and Hepatology

    Volume 18, Issue 7, July 2003, Pages: 756–762, ANDREW POULLIS, RUSSELL FOSTER, MICHAEL A MENDALL and MAGNE K FAGERHOL

    Version of Record online : 10 JUN 2003, DOI: 10.1046/j.1440-1746.2003.03014.x

  20. You have free access to this content
    Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings

    Alimentary Pharmacology & Therapeutics

    Volume 28, Issue 10, November 2008, Pages: 1221–1229, T. SIPPONEN, P. KÄRKKÄINEN, E. SAVILAHTI, K.-L. KOLHO, H. NUUTINEN, U. TURUNEN and M. FÄRKKILÄ

    Version of Record online : 26 AUG 2008, DOI: 10.1111/j.1365-2036.2008.03835.x